Adoption of immune checkpoint inhibitors (ICI) for unresectable locally advanced or metastatic urothelial carcinoma (u/mUC): A retrospective assessment of community oncology practices

被引：1
|
作者：
Aguilar, Kathleen M.
Grivas, Petros
Seal, Brian S.
Robert, Nicholas J.
Davies, Kalatu
Fleming, Mark T.
机构：
[1] Ontada, The Woodlands, TX USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[3] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[4] Ontada, Irving, TX USA
[5] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 28期
关键词：
D O I：
10.1200/JCO.2020.39.28_suppl.293
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
293
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma
    Hanna, Kirollos S.
    PHARMACOTHERAPY, 2017, 37 (11): : 1391 - 1405
  • [2] Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
    Lista, A. Gomez de Liano
    Necchi, A.
    Lavaud, P.
    Carles Galceran, J.
    Castellano, D.
    Ravaud, A.
    Duran, I.
    van Dijk, N.
    Giannatempo, P.
    Loriot, Y.
    Morales Barrera, R.
    De Velasco Oria De Rueda, G.
    Lefort, F.
    Martinez Bernal, G.
    Raggi, D.
    Gross-Goupil, M.
    Powles, T.
    van der Heijden, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts)
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma
    Meynard, Lucie
    Dinart, Derek
    Delaunay, Blandine
    Flechon, Aude
    Saldana, Carolina
    Lefort, Felix
    Gravis, Gwenaelle
    Thiery-Vuillemin, Antoine
    Cancel, Mathilde
    Coquan, Elodie
    Ladoire, Sylvain
    Maillet, Denis
    Rolland, Frederic
    Boughalem, Elouen
    Martin, Sophie
    Laramas, Mathieu
    Crouzet, Laurence
    Abbar, Baptiste
    Falkowski, Sabrina
    Pouessel, Damien
    Roubaud, Guilhem
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 43 - 53
  • [5] Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC)
    Pramod, Nikhil
    Dawsey, Scott
    Pavicic, Paul G.
    Lodha, Roshan
    Patgunarajah, Ubenthira
    Nair, Monica
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Wee, Christopher Eing
    Mian, Omar Y.
    Nizam, Amanda
    Nguyen, Jane
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies
    Katz, Heather
    Biglow, Layana
    Alsharedi, Mohamed
    JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (02) : 611 - 619
  • [7] Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies
    Heather Katz
    Layana Biglow
    Mohamed Alsharedi
    Journal of Gastrointestinal Cancer, 2020, 51 : 611 - 619
  • [8] Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC)
    Morales-Barrera, Rafael
    Vidal Casinello, Natalia
    Bonfill, Teresa
    Domenech, Montserrat
    Suarez Rodriguez, Cristina
    Puente, Javier
    Giner Joaquin, Julia
    Figols, Mariona
    Galante, Isabel
    Carrion, Albert
    Lopez, Hector
    Gonzalez, Macarena
    Roche, Sarai
    Mateo, Joaquin
    Gallardo Diaz, Enrique
    Fernandez Saez, Carlos
    Valverde Morales, Claudia Maria
    de Torres, Ines
    Morote, Juan
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] CIMUC: Chemotherapy following Immune checkpoints inhibitors in patients with locally advanced or metastatic urothelial carcinoma (la/mUC).
    Meynard, Lucie
    Dinart, Derek
    Flechon, Aude
    Saldana, Carolina
    Lefort, Felix
    Gravis, Gwenaelle
    Thiery-Vuillemin, Antoine
    Cancel, Mathilde
    Coquan, Elodie
    Ladoire, Sylvain
    Maillet, Denis
    Rolland, Frederic
    Boughalem, Elouen
    Martin, Sophie
    Laramas, Mathieu
    Crouzet, Laurence
    Abbar, Baptiste
    Falkowski, Sabrina
    Pouessel, Damien
    Roubaud, Guilhem
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345